Chinese biotech RemeGen (SHA: 688331) has reported positive late-stage clinical trial data for its dual-target fusion protein ...

US biotech Cartesian Therapeutics has reported that patients with generalized myasthenia gravis (gMG) continued to experience ...

"The same story is being repeated time and again," says Matthew, who is Head of Real Estate Securities at Gravis. "A bidder ...

MG-ADL (Myasthenia Gravis - Activities of Daily Living) provides a rapid clinical assessment of the patient's recall of symptoms impacting activities of daily living, with a total score range of 0 to ...

Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half of 2025. Click here to read more.

Nicholas J. Silvestri, MD, expects that the upcoming 2025 American Academy of Neurology Annual Meeting in San Diego will be an exciting event for the field of myasthenia gravis (MG), with ...

These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients.

"All three types of myasthenia gravis, based on antibody status ... a remission cannot be an expectation," he pointed out. "I'm looking forward to coming years when truly targeted therapies ...

From my colleague Allison DeAngelis: Over the last few years, the drug industry has rushed to retool CAR-T treatments for ...

HD Hyundai Construction Equipment and Devulon are bringing their next-generation models to this year’s bauma exhibition in ...

Responders to batoclimab in Period 1, defined as ≥2-point improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) score from baseline, were re-randomized 1:1:1 to batoclimab (340mg ...